Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.
Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Ann Surg. 2023 Apr 1;277(4):e941-e947. doi: 10.1097/SLA.0000000000005307. Epub 2021 Nov 18.
The aim of this study was to identify drivers of time from diagnosis to treatment (TTT) of surgically resected early stage non-small cell lung cancer (NSCLC) and determine the effect of TTT on post-resection survival.
Large database studies that lack relevant comorbidity data have identified longer TTT asa driver of worse overall survival.
From January 1, 2014 to April 1, 2018, 599 patients underwent lung resection for clinical stage I and II NSCLC. Random forest classification, regression, and survival were used to estimate likelihood of TTT = 0 (tissue diagnosis obtained at surgery), >0 (diagnosis obtained pre-resection), and effect of TTT on all-cause mortality.
Patients with TTT > 0 (n = 413) had median TTT of 42 days (25-75 th percentile: 27-59 days). Patients with TTT = 0 (n = 186) had smaller tumors and higher percent predicted forced expiratory volume in 1 second (FEV 1 %). Patients with history of stroke, oncology consultation, invasive mediastinal staging, low and high extremes of FEV 1 % had longer TTT. Higher clinical stage, lack of preoperative stress test, anemia, older age, lower FEV1% and diffusion lung capacity, larger tumor size, and longer TTT were the most important predictors of all-cause mortality. One- and 5-year overall survival decreased when TTT was >50 days.
Preoperative physiologic workup and multidisciplinary evaluation were the predominant drivers of longer TTT. Patients with TTT = 0have more favorable presentation and should be considered in TTT analyses for early stage lung cancer populations. The time needed to clinically stage and optimize patients for resection is not deleterious to overall survival until resection is performed after 50 days from diagnosis.
本研究旨在确定手术切除的早期非小细胞肺癌(NSCLC)治疗时间(TTT)的驱动因素,并确定 TTT 对术后生存的影响。
缺乏相关合并症数据的大型数据库研究已经确定较长的 TTT 是总生存率较差的驱动因素。
从 2014 年 1 月 1 日至 2018 年 4 月 1 日,599 例临床 I 期和 II 期 NSCLC 患者接受了肺切除术。随机森林分类、回归和生存用于估计 TTT = 0(手术时获得组织诊断)、>0(术前获得诊断)的可能性,以及 TTT 对全因死亡率的影响。
TTT > 0(n = 413)的患者中位 TTT 为 42 天(25-75 百分位:27-59 天)。TTT = 0(n = 186)的患者肿瘤较小,预测 1 秒用力呼气量(FEV 1 %)较高。有中风史、肿瘤咨询、侵袭性纵隔分期、FEV 1 %的低极端和高极端、较长的 TTT 患者。较高的临床分期、缺乏术前应激试验、贫血、年龄较大、较低的 FEV1%和弥散肺容量、较大的肿瘤大小和较长的 TTT 是全因死亡率的最重要预测因素。TTT > 50 天时,1 年和 5 年总生存率下降。
术前生理检查和多学科评估是导致 TTT 延长的主要因素。TTT = 0 的患者表现更有利,应在早期肺癌人群的 TTT 分析中考虑。从诊断到进行切除手术之前,需要 50 天以上的时间来进行临床分期并为患者进行切除手术,这不会对总体生存率产生不利影响。